Thanks to a new settlement with Catalyst, Teva is barred from marketing its Firdapse generic in the U.S. until Feb. 25, 2035, at the earliest. More: Catalyst settles with Teva, staving off Firdapse generic until 2035 Source: fierce
read moreHavas is forging deeper into the GLP-1 space with a series of YouTube videos about the drug class and its impact on the world. The ad agency is pitching the series as both a science-led initiative to separate fact from
read moreCDMO National Resilience plans to lay off roughly 120 workers at its Research Triangle Park facility in Durham, North Carolina, according to a notice filed with the state this week. The cuts will affect staffers Resilience inherited in its buyout
read more
New FDA-approved schizophrenia treatment shows promise in clinical trials More: Cambridge Cognition highlights positive Cantab results Source: News
read more
Investment to support RNA therapeutics for epilepsy and neurological disorders More: Angelini Ventures co-leads Series A financing in Neumirna Therapeutics Source: News
read moreNovo’s new insulin Awiqli and obesity prospect CagriSema are each expected to rake in billions by 2030, according to Clarivate Analytics’ Drugs to Watch in 2025 report. Lilly’s Ebglyss is also in line for a major haul. More: Launches from
read more© 1994 - 2026 B.M. Pharmaceuticals